Interim report 2026
Filed with HKEX · Stock code 1228 · · 85 pages · English
2 Definitions 5 Corporate Information 7 Business Highlights 10 Financial Highlights 11 Management Discussion and Analysis 32 56 Other Information Independent Review Report 58 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 59 Interim Condensed Consolidated Statement of Financial Position 61 Interim Condensed Consolidated Statement of Changes in Equity 62 I
CANbridge Pharmaceuticals Inc. on 6ix
Earlier from CANbridge Pharmaceuticals
- CANbridge Announces NHIA Reimbursement Approval of Livmarli for Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Taiwan
- CANbridge Announces Strategic Partnership and Investment from Baheal to Strengthen Commercialization of Rare Disease Products
- CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
- CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
- CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
Later from CANbridge Pharmaceuticals
All CANbridge Pharmaceuticals news releasesFollow CANbridge Pharmaceuticals into a list and get an email when it puts out news.
Follow CANbridge Pharmaceuticals